Fresh analysis reveals that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Research printed in a major health publication points out that while overweight people often shed substantial amounts of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Individuals buying such treatments must be cognizant of the risk of rapid rebound weight gain when the therapy is stopped," stated expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment mass within about a year and a half.
Analyzing Treatments
The research, which examined dozens of studies involving thousands of patients, contrasted the outcomes of the injectable medications with older methods.
Scientists emphasize that individuals who lose weight through diet and exercise typically experience a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Experts believe the mode of action of the jabs explains the heightened regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production could lead to the body to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making binge eating much more probable."
An Ongoing Issue?
The NHS suggest the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts argue that, given the high risk of relapse, the treatment might need to be life-long.
This opinion is reinforced by pharmaceutical companies, who note that the results "emphasize the persistent character of obesity," comparing it to managing diseases like hypertension.
User Experiences
Individuals who have come off the medication report a sudden return of hunger.
"It was like a trigger activating and you're instantly ravenous," recalled one woman.
This difficulty is compounded if users have not adopted lasting dietary or behavioural changes during therapy.
Growing Adoption
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Use is more common among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, experts caution that while these medications are powerful agents for weight loss, they are not a permanent fix and maintained weight loss relies on combined lifestyle changes.
